KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $136,630 | -79.6% | 17,383 | -82.4% | 0.00% | -66.7% |
| Q4 2022 | $669,341 | -86.7% | 99,015 | -71.5% | 0.00% | -90.0% |
| Q3 2022 | $5,037,000 | +8.9% | 347,125 | -26.1% | 0.03% | -57.7% |
| Q2 2022 | $4,625,000 | -33.2% | 470,000 | 0.0% | 0.07% | -16.5% |
| Q1 2022 | $6,928,000 | +11.4% | 470,000 | 0.0% | 0.08% | +34.9% |
| Q4 2021 | $6,218,000 | +196.9% | 470,000 | +291.7% | 0.06% | +600.0% |
| Q3 2021 | $2,094,000 | -27.2% | 120,000 | 0.0% | 0.01% | -43.8% |
| Q2 2021 | $2,875,000 | -6.7% | 120,000 | 0.0% | 0.02% | -5.9% |
| Q1 2021 | $3,083,000 | +83.0% | 120,000 | +103.8% | 0.02% | -26.1% |
| Q1 2019 | $1,685,000 | +182.7% | 58,871 | +94.9% | 0.02% | +109.1% |
| Q4 2018 | $596,000 | – | 30,201 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |